Dr. Bernstein will receive the 2007 Komen Brinker Award for Scientific Distinction in the category of clinical research.
Gray: Developing Technology to Solve Challenging Biomedical Problems
Joe W. Gray, Ph.D., is recognized as a pioneer in the development of innovative technologies that enable researchers to pursue original avenues of inquiry into challenging biomedical problems. The sum of his impact, innovation and creativity over the course of his career are directly linked to translational research which many leading scientists acknowledge will lead to real improvements for people living with breast cancer.
He is credited with the development and implementation of many important technologies, including high-speed sorting; flow karyotyping; the first chromosome painting probes; development of interphase fluorescent in situ hybridization (FISH); and the first demonstration using FISH showing ERBB2 amplification and BCR-ABL translocation, both of which are critically important to current patient management. His list of credits also includes brdU/DNA analysis of cell cycle progression; comparative genomic hybribidization (CGH); BAC End Sequencing (BES) and, more recently, nanotechnology.
Dr. Gray was an early adopter of technologies such as transcriptional
profiling, high throughput analysis, SNP array CGH and molecular inversion
probes. By integrating data received from these technologies, Dr. Gray has
made significant advancements in developing methods that will lead to
improved patient outcomes. Specifically, his work is leading to
groundbreaking research in the determination of how to improve breast
cancer detection and treatment. His efforts are helping to increase the
translation of basic research to the clinic. Dr. Gray is a staunch
proponent of collaborative, or "team" science. He supports an active
academic-industrial collaborative enterprise to en
|SOURCE Susan G. Komen for the Cure|
Copyright©2007 PR Newswire.
All rights reserved